ESC HF 2019 Joost Beusekamp shares results of his study on the association between potassium levels measured daily during hospitalization, treatment with RAASi and outcomes in acute HF patients.

ESC HF 2019 TmP/GFR is a novel parameter for tubular function. Lisa Emmens presents findings of her study on determinants of this parameter and its association with outcomes in HF patients.

ESC HF 2019 Jozine ter Maaten presents the results of her study on the effects of loop diuretics dosage on the ability to uptitrate RAASi in HFrEF patients and the association of loop diuretics dosage with outcomes.

ESC HF 2019 Michele Senni gives a short presentation of a subanalysis of the TRANSITION trial, comparing the rate of patients on sacubitril/valsartan after 10 weeks in de novo vs. previously diagnosed HFrEF patients.

ESC HF 2019 Prof. Rossignol talks about the AMBER trial and a prespecified analysis of HF patients. Patiromer use resulted in higher spironolactone maintenance in patients with resistant hypertension and CKD.

ESC HF 2019 In this debate, Douglas Packer and John Cleland took opposite sides of the statement that all patients with atrial fibrillation and heart failure should receive ablation. With poll.

ESC HF 2019 In a post-hoc analysis of the TRANSITION trial, a higher proportion patients on target dose for sacubitril/valsartan was observed in de novo HFrEF patients compared to prior diagnosed HFrEF patients.

ESC HF 2019 A subanalysis of the COMMANDER-HF trial demonstrated that low dose rivaroxaban decreased stroke/TIA risk in patients with HFrEF, sinus rhythm and CAD without increase in major bleeding.

ESC HF 2019 Addition of patiromer to spironolactone showed that a higher percentage of patients remained on spironolactone vs. those on placebo and spironolactone at the start, with no difference between HF or non-HF.

ESC HF 2019 In the PHARM-CH trial, a pharmacy-based intervention resulted in higher adherence to 3 HF medication classes in elderly, chronic HF patients and this intervention was safe.

ESC HF 2019 Classification based on congestion and hypoperfusion status was applied to a real-world population of acute HF patients, showing that wet-cold (congestion and hypoperfusion) profile was associated with worst outcomes.